← Back to headlines
Capricor Stock Rises as FDA Extends Deramiocel Action Date
Capricor's stock has seen a rise after the FDA announced an extension to the action date for its drug Deramiocel.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
